Continuous subcutaneous infusion of foslevodopa/foscarbidopa was safe and improved motor complications in patients with advanced Parkinson’s disease, according to data presented at the European Academy of Neurology Congress 2022.
“ABBV-951 (foslevodopa/foscarbidopa) is a solution of levodopa and carbidopa prodrugs for continuous subcutaneous infusion being investigated for the treatment of advanced Parkinson’s disease in patients whose motor symptoms are not controlled by oral medications,” Jason Aldred, MD, FAAN, of Selkirk Neurology & Inland Northwest Research in